Abstract
Several models have been proposed to predict target plasma concentrations for new anticancer drugs in humans. Collins et al. (1) have suggested a dose-escalation scheme based on the optimally determined plasma concentration-versus-time (CXT) product in mouse models. Phase I human studies are initiated at a dose of onetenth the LD10 in mice. Then, human pharmacology studies are conducted to determine plasma CXT data in patients. The dose is then escalated to approach a plasma CXT equal to that achieved in the mouse model.
Keywords
- Anticancer Drug
- Human Pharmacology Study
- Standard Anticancer Drug
- Brequinar Sodium
- Clinical Pharmacology Trial
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Collins JM, Zaharko DS, Dedrick RL et al: Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat. Rep. 70:73–80, 1986.
Scheithauer W, Clark GM, Salmon SE et al: Model for estimation of clinically achievable plasma concentrations for investigational anti-cancer drugs in man. Cancer Treat. Rep. 70:1379–1382, 1986.
Davis LE, Alberts DS, Plezia PM et al: Predictive model for plasma concentration versus time profiles of investigational anticancer drugs in patients. JNCI 80:815–819, 1988.
Alberts DS, Chen HS: Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Cloning of Human Tumor Cells, SE Salmon (ed), Liss, New York, pp. 351–359, 1980.
Sommadossi JP, Aubaert C, Cano JP et al: Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans. Cancer Res. 43:930–933, 1981.
Marsh KC, Liesmann J, Patton TF et al: Plasma levels and urinary excretion of methyl-GAG following iv infusion in man. Cancer Tret. Rep. 65:253–257, 1981.
Snedecor GW, Cochran WG: Statistical methods. Ames, IA: The Iowa State University Press, 1967.
Arteaga CL, Brown TD, Kuhn JG et al: Phase I clinical and pharmacokinetic trial of brequinar sodium (DUP 785; NSC 368390). Cancer Res. 49:4648–4653, 1989.
Harman GS, Craig JB, Kuhn JG et al: Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule. Cancer Res. 48:4706–4710, 1988.
Lam K, Alberts DS, Peng YM et al: Phase I and pharmacokinetic study of BW502U83 (an arylmethyl aminopropanediol) in cancer patients. Proc. Amer. Soc. Clin. One. 9:68, 1990.
Data on file, Burroughs Wellcome Co., Research Triangle Park, NC, 1990.
Data on file, Dupont Co., Wilmington, DE, 1989.
Freireich EJ, Gehan EA, Rail DP et al: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50:219–245, 1966.
Goldsmith MA, Slavik M, Carter SK: Quantitative prediction of drug toxicity in humans in small and large animals. Cancer Res. 35:1354–1364, 1975.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Alberts, D.S., Roe, D.J., Plezia, P.M., Kuhn, J.G., Davis, L.E. (1992). Prospective Evaluation of a Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patients. In: Valeriote, F.A., Corbett, T.H., Baker, L.H. (eds) Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Developments in Oncology, vol 68. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3492-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3492-1_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6548-8
Online ISBN: 978-1-4615-3492-1
eBook Packages: Springer Book Archive